Antiviral drug maker Gilead is among the investors that have backed the cell therapy startup’s $25m round.
US-based cell therapy developer Kyverna Therapeutics secured $25m in a series A round yesterday from backers including biopharmaceutical firm Gilead Sciences.
Life sciences-focused venture capital firms Vida Ventures and Westlake Village Biopartners also joined the round. The latter two were identified as Kyverna’s founding investors, though further details were not revealed.
Founded in 2018, Kyverna develops cell therapies to treat autoimmune diseases. The cash will support Kyverna’s efforts to advance T-cell therapies from its T-cell engineering and synthetic biology platform…
